Search results
Moderna Litigation Against BioNTech and Pfizer Stayed Pending IPR | JD Supra
JD Supra· 2 weeks agoWe previously reported on the litigation brought by ModernaTX, Inc. and Moderna US, Inc. (collectively, “Moderna”) against BioNTech SE, BioNTech...
Here's How to Play Pfizer (PFE) Stock Ahead of Q1 Earnings
Zacks via Yahoo Finance· 2 weeks agoPfizer (PFE) expects its operational revenues to improve, driven by its in-line products like...
BioNTech (BNTX) to Report Q1 Earnings: Is a Beat in Store?
Zacks via Yahoo Finance· 2 weeks agoOn BioNTech's (BNTX) first-quarter 2024 earnings call, investors' focus is likely to be on the...
Novavax Soars on $1.2 Billion Sanofi Vaccine Licensing Deal
Bloomberg via Yahoo Finance· 1 day ago(Bloomberg) -- Novavax Inc. shares surged after the company signed a $1.2 billion licensing...
Jacob Rees-Mogg claims UK government 'downplayed' risks of AstraZeneca COVID vaccine
Yahoo News UK· 1 day agoIn the first year, vaccinations were estimated to have prevented 19.8 million COVID-19 deaths...
Pfizer (PFE) Q1 Earnings & Sales Top, EPS Guidance Raised
Zacks via Yahoo Finance· 1 week agoThe revenue decline, as expected, was due to a steep drop in revenues from its COVID-19 products,...
What's Going With BioNTech Stock On Monday?
Benzinga· 5 days agoMonday, BioNTech SE BNTX reported a first-quarter EPS loss of 1.31 euros ($1.41 loss), a shift from an income of 2.05 euros, missing the consensus loss...
Pfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?
Investor's Business Daily· 3 days agoSo, all in all, is PFE stock a buy or a sell right now? Pfizer Stock Fundamentals: 'Massive' Upside...
BioNTech Lifts As Covid Sales Plummet With 90% Of Revenue Still To Come
Investor's Business Daily· 5 days agoSales of Comirnaty, the BioNTech-Pfizer-partnered Covid shot, plummeted 86% to $202 million,...
Pfizer Jumps On 'Massive' First-Quarter Upside Thanks To Paxlovid Surprise
Investor's Business Daily· 1 week agoPfizer stock surged Wednesday after the pharma giant walloped analysts' first-quarter earnings...